Ajouter à une liste

Instrument Inactif

Communiqués MAXO CAP

Actions

JMAC

US57778T1060

Communiqués

30/03/23	Apollomics Announces Completion of Business Combination and Listing on Nasdaq	AQ
21/03/23	MAXPRO CAPITAL ACQUISITION CORP. : Submission of Matters to a Vote of Security Holders, Other Events (form 8-K)	AQ
10/02/23	MAXPRO CAPITAL ACQUISITION CORP. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)	AQ
13/01/23	MAXPRO CAPITAL ACQUISITION CORP. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
13/01/23	Maxpro Capital Acquisition Corp. Confirms Additional Funding and Extension of Deadline to Complete Initial Business Combination	AQ
10/01/23	MAXPRO CAPITAL ACQUISITION CORP. : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
10/01/23	Maxpro Capital Acquisition Corp. Announces Extension to Deadline to Complete Business Combination	AQ
29/11/22	MAXPRO CAPITAL ACQUISITION CORP. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)	AQ
16/11/22	Apollomics Inc. Receives FDA Orphan Drug Designation for Vebreltinib (APL-101) for Treatment of Non-Small Cell Lung Cancer with MET Genomic Tumor Aberrations	AQ
02/11/22	MAXPRO CAPITAL ACQUISITION CORP. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ
14/10/22	MAXPRO CAPITAL ACQUISITION CORP. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
14/10/22	Maxpro Capital Acquisition Corp. Confirms Additional Funding and Extension of Deadline to Complete Initial Business Combination	AQ
07/10/22	MAXPRO CAPITAL ACQUISITION CORP. : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
07/10/22	Maxpro Capital Acquisition Corp. Announces Extension to Deadline to Complete Business Combination	AQ
14/09/22	MAXPRO CAPITAL ACQUISITION CORP. : Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
14/09/22	Apollomics Inc., a Late-Stage Clinical Biopharmaceutical Company to be Listed on Nasdaq Through Business Combination with Maxpro Capital Acquisition Corp.	AQ
11/08/22	MAXPRO CAPITAL ACQUISITION CORP. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ
16/05/22	MAXPRO CAPITAL ACQUISITION CORP. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ
31/03/22	MAXPRO CAPITAL ACQUISITION CORP. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Articles Zonebourse Analyses Zonebourse

Filtres

Dès maintenant, trouvez facilement les meilleurs investissements de demain !

×